Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26623694 | 0.82 | ALDH1A1 (0.35) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL27165392 | 0.80 | KMT2A (0.34) | KMT2AATMALDH1A1PKM | |
| SCHEMBL9224514 | 0.75 | KMT2A (0.40) | KMT2AATMALDH1A1PKM | |
| SCHEMBL3487387 | 0.75 | KMT2A (0.44) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL3801263 | 0.74 | KMT2A (0.46) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL4503936 | 0.74 | KMT2A (0.36) | KMT2AATMALDH1A1PKM | |
| SCHEMBL28469683 | 0.73 | KMT2A (0.38) | KMT2AATM | |
| SCHEMBL4261255 | 0.72 | ALDH1A1 (0.42) | KMT2AATMALDH1A1PKM | |
| SCHEMBL4654434 | 0.71 | ALDH1A1 (0.40) | KMT2AATMALDH1A1PKMSLC1A2 | |
| SCHEMBL604671 | 0.71 | ALDH1A1 (0.56) | KMT2AATMALDH1A1PKMSLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580694-A1 | SEALANTS FOR TISSUE CLOSURE | Ethicon, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2024047443-A1 | SEALANTS FOR TISSUE CLOSURE | ETHICON, INC. (US) | 2024-03-07 | — | — | WO | claimed |
| US-20240066178-A1 | SEALANTS FOR TISSUE CLOSURE | ETHICON, INC. (US) | 2024-02-29 | — | — | US | claimed |
| US-20230310320-A1 | SOLUBLE MICROCARRIER, METHOD FOR MANUFACTURING AND METHOD OF USE THEREOF | NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2023-10-05 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| WO-2012162490-A1 | NANOZYME COMPOSITIONS AND METHODS OF SYNTHESIS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-11-29 | — | — | WO | claimed |
| JP-4193917-B2 | — | — | 2008-12-10 | — | — | JP | claimed |
| EP-0832201-B1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | UNIV ARIZONA (US) | 2005-10-05 | — | — | EP | claimed |
| US-20030149173-A1 | Crosslinked polymer compositions and methods for their use | RHEE WOONZA M (US) | 2003-08-07 | — | — | US | claimed |
| US-20030143638-A1 | Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2003-07-31 | — | — | US | claimed |
| US-20020013408-A1 | Cross-linked polymer compositions and methods for their use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2002-01-31 | — | — | US | claimed |
| US-20010003126-A1 | Method of making crosslinked polymer matrices in tissue treatment applications | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2001-06-07 | — | — | US | claimed |
| US-6093541-A | WITH METAL PRESENTATION SURFACE HAVING IMMOBILIZED COMPLEX OF TETHERING MOLECULE AND DIGESTION MOLECULE; FOR RAPID AND EFFICIENT ANALYSIS OF BIOMOLECULES USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION TECHNIQUE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 2000-07-25 | — | — | US | claimed |
| JP-2000502380-A | — | — | 2000-02-29 | — | — | JP | claimed |
| EP-0876165-A1 | CROSSLINKED POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | COLLAGEN CORPORATION (US) | 1998-11-11 | — | — | EP | claimed |
| WO-1997022371-A9 | CROSSLINKED POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | — | 1997-09-04 | — | — | WO | claimed |
| WO-1997022371-A1 | CROSSLINKED POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | COLLAGEN CORPORATION (US) | 1997-06-26 | — | — | WO | claimed |
| US-12599624-B2 | Biodegradable lung sealants | ETHICON, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-0359996-A2 | Synthetic amino acid-and/or peptide-containing graft copolymers | Al Marzook United Commercial Co. (KW) | 1990-03-28 | — | — | EP | disclosed |
| US-4908404-A | Water soluble high molecular weight cationic graft polymer | BIOPOLYMERS, INC. (US) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599624-B2 | Biodegradable lung sealants | CD44, TTPA, PLOD3 | KMT2A 2895/4885ATM 326/4885ALDH1A1 678/4885 |
| US-20030143638-A1 | Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method | CD79B, CD99, PA2G4 | KMT2A 2801/4885ATM 2400/4885ALDH1A1 3777/4885 |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | KMT2A 2178/4885ATM 4398/4885ALDH1A1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.